medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 1

<< Back Next >>

Gac Med Mex 2017; 153 (1)

Association of V249I and T280M variants of fractalkine receptor CX3CR1 with carotid intima-media thickness in a mexican population with type 2 diabetes

Gómez-Díaz RA, Gutiérrez J, Contreras-Rodriguez A, Valladares-Salgado A, Tanus-Hajj J, Mondragón-González R, Talavera JO, Mejía-Benitez MA, García-Mena J, Cruz M, Wacher NH

Language: English
References: 44
Page: 49-56
PDF size: 106.96 Kb.


ABSTRACT

Objective: To evaluate the association of the V249I and T280M variants of CX3CR1 fractalkine gene with carotid intima-media thickness in Mexican subjects with and without type 2 diabetes. Methods: We analyzed the V249I and T280M variants of the CX3CR1 receptor by TaqMan assays in 111 subjects with type 2 diabetes and 109 healthy controls. Hemoglobin A1c, glucose, and lipid profile were determined. Results: A significant increase in carotid intima-media thickness was observed in type 2 diabetes patients (0.979 ± 0.361 mm) compared to healthy controls (0.588 ± 0.175 mm). In subjects carrying the MM variant of the T280M polymorphism, hemoglobin A1c was higher (p = 0.008). Classic risk factors for atherosclerosis showed no differences between carriers of the T280M and V249I variants. Controls with the II249 genotype associated with carotid intima-media thickness (0.747 ± 0.192 mm; p = 0.041), and this difference remained significant even after adjusting factors such as age, gender, and body mass index (OR: 7.7; 95% CI: 1.269-47.31; p = 0.027). Conclusions: V249I genotype of the fractalkine receptor showed a protector role in patients with type 2 diabetes. The T280M genotype is associated with increased carotid intima-media thickness in Mexican individuals with or without type 2 diabetes.


REFERENCES

  1. Van der Heijden AA, van’t Riet E, Bot SD, et al. Risk of recurrent cardiovascular event in individuals with type 2 diabetes of intermediate hyperglycemia: The Hoorn Study. Diabetes Care. 2013;36:3498-502.

  2. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33:442-9.

  3. Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med. 2007;262:408-14.

  4. Okayama KI, Mita T, Gosho M, et al. Carotid intima-media thickness progression predicts cardiovascular events in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;101:286-92.

  5. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21:93-111.

  6. Napoli N, Zardi E, Strollo R, et al. Increased carotid thickness in subjects with recently-diagnosed diabetes from rural Cameroon. PLoS One. 2012;7:e41316.

  7. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3Cl1). Circulation. 2003;108:2498-504.

  8. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-4.

  9. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521-30.

  10. Flierl U, Schäfer A. Fractalkine--a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost. 2012;108:457-63.

  11. Matsumiya T, Ota K, Imaizumi T, Yoshida H, Kimura H, Satoh K. Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF- alpha in post-transcriptional regulation of CX3CL1. J Immunol. 2010;184:4205-14.

  12. Gan AM, Butoi ED, Manea A, et al. Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways. Cell Tissue Res. 2013;351:161-74.

  13. Ramos MV, Fernández GC, Brando RJ, et al. Interleukin-10 and interferon- gamma modulate surface expression of fractalkine-receptor (CX(3) CR1) via PI3K in monocytes. Immunology. 2010;129:600-9.

  14. Franco L, Williams FM, Trofimov S, Surdulescu G, Spector T, Livshits G. Elevated plasma fractalkine levels are associated with higher levels of IL-6, Apo-B, LDL-C and insulin, but not with body composition in a large female twin sample. Metabolism. 2013;62:1081-7.

  15. Shah R, Hinkle CC, Ferguson JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes. 2011;60:1512-8.

  16. Stolla M, Pelisek J, von Brühl MLet al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One. 2012;7:e43572.

  17. Richter B, Koller L, Hohensinner PJ, et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost. 2012;108:1220-7.

  18. Njerve IU, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I. Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus. Metab Syndr Relat Disord. 2012;10:400-6.

  19. Postea O, Vasina EM, Cauwenberghs S, et al. Contribution of platelet CX(3) CR1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. Arterioscler Thromb Vasc Biol. 2012;32:1186-93.

  20. Fumagalli S, Perego C, Ortolano F, De Simoni MG. CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia. 2013;61:827-42.

  21. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 1994;12:593-633.

  22. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL. Effects of fractalkine receptor variants on common carotid artery intimamedia thickness. Stroke. 2006;37:1558-61.

  23. Niessner A, Marculescu R, Haschemi A, et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation. Thromb Haemost. 2005;93:949-54.

  24. Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity (Silver Spring). 2011;19:222-7.

  25. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):S67-74.

  26. Mejía-Benítez A, Klünder-Klünder M, Yengo L, et al. Analysis of the contribution of FTO, NPC1, ENPP1, NEGR1, GNPDA2 and MC4R genes to obesity in Mexican children. BMC Med Genet. 2013;14:21.

  27. Wallace GR, Vaughan RW, Kondeatis E, et al. A CX3CR1 genotype associated with retinal vasculitis in patients in the United Kingdom. Invest Ophthalmol Vis Sci. 2006;47:2966-70.

  28. Ghilardi G, Biondi ML, Turri O, Guagnellini E, Scorza R. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke. 2004;35:1276-9.

  29. Li C, Lu SC, Hsieh PS, et al. Distribution of human chemokine (C-X3-C) receptor 1 (CX3CR1) gene polymorphisms and haplotypes of the CC chemokine receptor 5 (CCR5) promoter in Chinese people, and the effects of CCR5 haplotypes on CCR5 expression. Int J Immunogenet. 2005;32:99-106.

  30. Lee KY, Sohn YH, Baik JS, Kim GW, Kim JS. Arterial pulsatility as an index of cerebral microangiopathy in diabetes. Stroke. 2000;31:1111-5.

  31. Su TC, Chien KL, Jeng JS, et al. Age- and gender-associated determinants of carotid intima-media thickness: a community-based study. J Atheroscler Thromb. 2012;19:872-80.

  32. Shah AS, Dolan LM, Kimball TR, et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:3740-5.

  33. Liu YP, Zhan WW, Zhang YF, et al. Carotid intima-media thickness and stiffness in relation to type 2 diabetes in Chinese. Endocrine. 2007;31: 289-93.

  34. O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media thickness. Eur Heart J. 2010;31:1682-9.

  35. Moore XL, Michell D, Lee S, et al. Increased carotid intima-media thickness and reduced distensibility in human class III obesity: independent and differential influences of adiposity and blood pressure on the vasculature. PLoS One. 2013;8:e53972.

  36. George JM, Bhat R, Pai KM, S A, Jeganathan J. The carotid intima media thickness: a predictor of the clinical coronary events. J Clin Diagn Res. 2013;7:1082-5.

  37. Debette S, Bevan S, Dartigues JF, et al. Fractalkine receptor/ligand genetic variants and carotid intima-media thickness. Stroke. 2009;40:2212-4.

  38. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925-8.

  39. Kimouli M, Miyakis S, Georgakopoulos P, Neofytou E, Achimastos AD, Spandidos DA. Polymorphisms of fractalkine receptor CX3CR1 gene in patients with symptomatic and asymptomatic carotid artery stenosis. J Atheroscler Thromb. 2009;16:604-10.

  40. Cefalu WT. Fractalkine: a cellular link between adipose tissue inflammation and vascular pathologies. Diabetes. 2011;60:1380-2.

  41. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001;89:401-7.

  42. McDermott DH, Fong AM, Yang Q, et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111; 1241-50.

  43. Niessner A, Marculescu R, Haschemi A, et al. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation. Thromb Haemost. 2005;93:949-54.

  44. Lavergne E, Labreuche J, Daoudi M, et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:847-53.




2020     |     www.medigraphic.com